Experts expect the personalised melanoma vaccine to receive US approval in 2027 following positive late-stage trial results.
- Intismeran autogene (V940)
- KEYTRUDA
- FDA
New Scientist, Carissa Wong
Kalshi
Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?59¢to90¢
Markets
PriceMoveHead startNowReports
- 0sFirstNew Scientist, Carissa Wong
- +1h 6mRepeatedNew Scientist
- +26h 49mRepeatedNew Scientist
- +9dRepeatedNew Scientist
- +9d59¢to90¢